Evolution has provided a number of animal species with extraordinary phenotypes. Several of these phenotypes allow species to survive and thrive in environmental conditions that mimic disease states in humans. The study of evolved mechanisms responsible for these phenotypes may provide insights into the basis of human disease and guide the design of new therapeutic approaches. Examples include species that tolerate acute or chronic hypoxemia like deep-diving mammals and high-altitude inhabitants, as well as those that hibernate and interrupt their development when exposed to adverse environments. The evolved traits exhibited by these animal species involve modifications of common biological pathways that affect metabolic regulation, organ function, antioxidant defenses, and oxygen transport. In 2006, the National Heart, Lung, and Blood Institute released a funding opportunity announcement to support studies that were designed to elucidate the natural molecular and cellular mechanisms of adaptation in species that tolerate extreme environmental conditions. The rationale for this funding opportunity is detailed in this article, and the specific evolved mechanisms examined in the supported research are described. Also highlighted are past medical advances achieved through the study of animal species that have evolved extraordinary phenotypes as well as the expectations for new understanding of nature's solutions to heart, lung, blood, and sleep disorders through future research in this area. (Circ Res. 2012; 110:915-921.)
I n 2007, cardiovascular, respiratory, and blood diseases accounted for more than one million deaths and 43% of all deaths in the United States. 1 Of all diseases, heart disease is the leading cause of death, cerebrovascular disease is third (behind cancer), and chronic obstructive pulmonary disease ranks fourth. 1 Despite a 12% decline in the number of deaths from heart, lung, and blood diseases from 1987 to 2007, the public health burden and economic costs remain high, 1, 2 and new effective interventions and treatments are needed. Innovative research approaches will improve understanding of the molecular and physiological basis of human health and disease. One successful and often unexploited strategy in biomedical research is to examine naturally occurring variations in animal species that are adapted to extreme environments. This approach follows August Krogh's principle that "for a large number of problems, there will be some animal of choice or a few such animals on which it can be most conveniently studied." 3 Krogh's principle is based on the observation that some organisms are particularly well-suited for studying specific problems that affect humans-ie, they have evolved phenotypes that exemplify a phenomenon observed in humans, mimic essential aspects of a particular human disease, or permit a unique study approach. Krogh believed that these specialized adaptations could and should be exploited to solve specific biological problems.
One example of the application of Krogh's principle that advanced biomedical knowledge is the work performed on electric rays (Torpedo californica) and eels (Electrophorus electricus). These species were studied because they represented explicit examples of "animal electricity," 4,5 characterized by their specialized electric organs that allow them to generate electric fields for communication, navigation, predation, and defense without shocking themselves. Work on electric rays and eels resulted in fundamental understanding of the molecular properties of acetylcholine receptors and membrane-bound ion channels. 6 Venoms, another evolved strategy in some animal species for self-defense and seeking prey, initially piqued the interest of scientists because of their paralyzing potency. 7 The study of venom from sessile marine mollusks (genus Conus) resulted in the identification of several conotoxins, peptides with high affinities for human ion channels. 8 One of these peptides, -conotoxin MVIIA from Conus magnus, selectively blocks N-type voltage-gated Ca 2ϩ channels, which control norepinephrine release from cardiac sympathetic nerves 9 and other neural pathways. 10 The -conotoxin MVIIA's synthetic equivalent, ziconotide, is Food and Drug Administration-approved for treating neuropathic pain in cancer and AIDS patients, 11 and it has therapeutic potential for ischemic stroke 12 and other cardiovascular, respiratory, and blood diseases. Similarly, studies of venom from the American funnel web spider (Agelenopsis aperta) identified peptides with high affinities for ion channels in humans and other species. 13 One such peptide, -agatoxin IIA, specifically targets T-type and N-type voltage-gated Ca 2ϩ channels, which are involved in the development of congestive heart failure, hypertension, and epilepsy. 14 Further studies with -agatoxin IIA may offer new therapeutic strategies for treating and preventing these diseases. The study of vampire bats (Desmodus rotundus) also supports Krogh's principle. Bites inflicted by these bats were known to bleed freely for several hours after they finished feeding, 15 and biomedical investigators were interested in understanding how vampire bat saliva prevented blood coagulation in the host animal so that this knowledge might be used to improve therapeutic outcomes in people with hypercoagulability syndromes and other cardiovascular disorders. These studies led to the characterization of plasminogen-activating proteins in vampire bat saliva, 16 which subsequently resulted in the development and phase III clinical trial testing of desmoteplase, 17 a new anticoagulant for stroke treatment. 18 Krogh's principle also has been applied in research aimed at understanding the nervous system by using animal models with unique phenotypes. Giant axons from squid (Loligo ssp) were ideal for studies designed to elucidate the bases of neural activity because of their large physical size, which allowed the placement of recording electrodes across the membrane of a single neuron. This ability allowed the development of voltage clamp techniques to measure changes in the membrane current underlying an action potential, and it also spurred experimental protocols to decipher the ionic bases of those currents. This pioneering work in giant squid axons led to the fundamental understanding of the ionic bases for resting and action potentials in nerves 19 and other excitable tissues, including heart. 20 Similarly, the investigation of sea slugs (genus Aplysia) was undertaken because they possessed a relatively small number of large nerve cells that were easily identified and could be individually mapped. 21, 22 Sea slugs exhibited a siphon withdrawal response mediated by electric synapses that allowed several neurons to fire simultaneously to permit a rapid reaction to danger. 23 The unique configuration of synapses in these species aided studies that were designed to elucidate the basis of memory. [21] [22] [23] Comparative biology also has identified species with unique phenotypes that naturally mimic or accentuate aspects of human disease conditions. For example, "fainting goats," which had skeletal muscle rigidity and collapsed when startled, appeared to share symptoms of human congenital myotonia, a neuromuscular disease characterized by slow muscle relaxation after contraction or electric stimulation. Studies demonstrated that before stimulation, resting muscle fibers from this strain of goats had abnormal chloride channel kinetics because of ion channel protein mutations. 24 This finding, along with myotonic mice studies, 25 led to the prediction of the location of the Becker myotonia gene in humans 26 before the major chloride channel in mammalian skeletal muscle had been cloned. 27 Burmese pythons (Python molurus) also mimic and accentuate aspects of human disease conditions with their unique responses after ingesting large prey. Fasting pythons have reduced stomach volume, decreased intestinal mass, and "normal" heart volumes. However, within 48 to 72 hours after feeding, pythons undergo massive remodeling of their entire digestive system and a 40% increase in heart mass. 28 Most mammalian models of hypertrophy, however, only exhibit modest myocardial hypertrophy (approximately 10% to 20%) after weeks of stimulation. 29, 30 These responses in pythons allow them to serve as unique models of digestive physiology, metabolic regulation, and cardiac hypertrophy. Thus far, studies show that python heart growth is characterized by myocyte hypertrophy in the absence of cell proliferation through the activation of signaling pathways for fatty acid transport and oxidation. 31 A combination of fatty acids, identified in python plasma after ingestion of a large meal, promotes hypertrophy in mammalian cardiac myocytes. 31 This finding suggests the possibility that fatty acid supplementation might provide a new mechanism to modify cardiac gene expression and function and could be used to enhance cardiac performance in humans with cardiovascular disease.
Thus, in accordance with Krogh's principle, the understanding of human health and disease has been greatly aided by investigations of animal species with extraordinary evolved phenotypes. With this in mind, the National Heart, Lung, and Blood Institute in 2006 released two funding opportunity announcements entitled "Elucidating Nature's Solutions to Heart, Lung, and Blood Diseases and Sleep Disorder Processes." 32, 33 The overall goal was to support "studies that elucidate the natural molecular and cellular 
Hibernators
Hibernation is a successful survival strategy used by many species. For instance, mammalian hibernators in harsh winter conditions intolerable to other species and humans typically reduce their metabolism to approximately 1% of normal rates, decrease heart rate to approximately 5% of normal values, and suppress body temperatures to as low as Ϫ2°C without apparent harm. 34 Unlike nonhibernators and humans, 35 coldclimate hibernators selectively maintain vital organ function (eg, brain and heart) and are not susceptible to detrimental cardiovascular effects resulting from the low temperatures. 36 -38 Distinguishing characteristics of the hibernator's heart that differ from that of the nonhibernator include the activation of signaling pathways elicited by ischemic preconditioning, 37, 39 changes in electric properties, 40, 41 maintenance of Na ϩ /K ϩ ion homeostasis, 42 and proteome alterations. 43 During arousal from hibernation, hibernators do not experience tissue damage resulting from oxidative stress, as experienced in nonhibernators. 44 -46 Future research to determine the mechanisms that allow hibernators to survive dramatic seasonal changes likely will require elucidating the differential expression of mRNA and proteins, as well as protein post-translational modifications, which distinguish summeractive animals from their winter-hibernating counterparts. Further studies will elucidate how nonhibernators can be protected from ischemia/reperfusion injury when they are induced to enter a reversible hibernation-like (ie, hypometabolic) state with hydrogen sulfide (H 2 S), which acts as a vasodilator in the heart. 47, 48 Such a strategy might be applied to patients with out-of-hospital cardiac arrest or severe traumatic injury, permitting them to be placed in a state of medically induced hibernation so more time could be taken to transport them to an emergency department or hospital facility where advanced life-saving interventions, including surgery, would be initiated. 49 Understanding the strategies that allow hibernators to dramatically reduce their metabolic rates and tolerate cold temperatures also may result in development of better methods to preserve human organs before transplantation, 50,51 improved resuscitation outcomes, 49 insight for protection against ischemia/reperfusion injury, 51, 52 and care for patients exposed to severe accidental hypothermia. 53
Anoxia-Tolerant Species That Suspend Development in Adverse Conditions
Study of the evolved physiological mechanisms in species tolerant to O 2 deprivation also may contribute to the development of new therapeutic strategies to minimize morbidity and mortality in patients with out-of-hospital cardiac arrest and severe traumatic injury. 54 Anoxia-tolerant and hypoxia- tolerant species appear to share several characteristics (eg, higher hemoglobin-O 2 saturation, lower metabolic rate, blood flow redistribution, and optimization of O 2 usage). One survival strategy used by animal species that normally endure prolonged O 2 deprivation is to enter diapause (ie, developmental arrest). Diapause occurs in a number of species, but it is most often observed in arthropods and egg-laying fish (eg, annual killifish Austrofundulus limnaeus). 55 The specific biochemical signaling pathways that regulate metabolic control and stress tolerance during diapause vary from organism to organism, but they share some common properties, which include a termination signal before development resumes and the accumulation of molecular chaperones (ie, heat shock proteins). 56 Other processes likely involved in diapause and in the regulation of biochemical pathways that exist in all animal species include metabolic control by adenosine monophosphate-activated protein kinase 57 or phosphoenolpyruvate carboxykinase, 58 as well as reactive oxygen species/ reactive nitrogen species signaling, resulting in posttranslational modifications that affect protein activity. 59 These pathways are being further investigated at the molecular level, 56 and insights gained from these studies will complement current knowledge of these processes in other animal species. Studies of mitochondrial physiology in diapausing species suggest that intrinsic regulation of electron transport and proton leak across the inner mitochondrial membrane may underlie anoxia tolerance, 60 a mechanism that someday might be triggered and used in patients with chronic obstructive lung disease.
Elucidation of the mechanisms that initiate and maintain diapause has contributed to the understanding of early human embryonic growth, delayed embryo transplantation, and cryopreservation. 61, 62 In future work with anoxia-tolerant species, it will be important to determine how metabolic depression results in reduced energy consumption, identify what pathways support anaerobic metabolism, understand how mitochondrial physiology is regulated during anoxia/hypoxia, and explore the role of transcription factors, miRNA, and epigenetics in anoxia tolerance.
High-Altitude Inhabitants
Animal species that have adapted to life at high altitudes also serve as models for elucidating the cellular and molecular mechanisms of tolerance to hypoxia-induced hypoxemia similar to conditions experienced by humans with anemia or chronic obstructive pulmonary disease. 63, 64 For instance, deer mice that are native to altitudes more than 4000 meters have evolved elevated hemoglobin-O 2 affinities relative to their lowland counterparts, which help to safeguard arterial O 2 saturation under hypoxic conditions. [65] [66] [67] The chronic hypoxia experienced by animal species that dwell at high altitudes is similar to that observed in patients with conditions resulting in insufficient blood flow (eg, cerebrovascular hemorrhage, vascular occlusion, cardiac arrest, or bypass surgery) or respiratory dysfunction (eg, airway obstruction, asthma, emphysema, or lung dysfunction). Identifying and characterizing the molecular mechanisms of hemoglobin adaptation to hypoxia, for instance, may guide the design of recombinant hemoglobins for use as O 2 carriers to enhance tissue O 2 supply in patients with hemorrhagic shock, hemolysis, and ischemic insult in humans. 68, 69 Further studies of adaptive changes in blood-O 2 transport at high altitudes also could aid the development of new therapeutic interventions for highaltitude-induced sleep apnea 70 and various forms of chronic mountain sickness. 71, 72 The most prominent characteristic of chronic mountain sickness is excessive polycythemia, which leads to blood hyperviscosity, pulmonary hypertension, cerebral hypoperfusion, heart failure, and death. 71, 72 Pharmacological interventions to reduce and prevent the chronic mountain sickness erythropoietic response are currently available, 73 but a safe and effective therapeutic approach to chronic mountain sickness for large-scale use remains lacking. 74 The challenge for future hypoxia research is to explore the cellular mechanisms and conditions that reconfigure an organ or cellular network into a hypometabolic state.
Diving Mammals
Diving mammals endure a variety of environmental stresses, and they have evolved physiological mechanisms that result in changes in respiratory drive, blood flow distribution, and heart rate to permit them to tolerate long periods of activity underwater without inhaling oxygen. 75, 76 Understanding these reflex responses and how they may be used in patients has provided therapeutic interventions. For example, an induced "diving reflex" is a recognized therapeutic intervention useful in terminating supraventricular tachycardia, a sustained arrhythmia, in children. 77, 78 Increased understanding of the mechanisms that allow diving mammals to remain submerged for long durations and tolerate periods when arterial blood oxygen tension (PO 2 ) decreases to anoxic levels in humans and land mammals might be useful in understanding, treating, and preventing some cardiovascular disorders and sleep disorders. During extended dives, coronary blood flow in seals may decrease to as low as approximately 10% of predictive values, 79 a level comparable to that observed in infarcted dog myocardium, 80 and arterial PO 2 may be less than 20 torr. 81 To prevent arterial blood PO 2 from declining, diving mammals dramatically elevate myoglobin content in their skeletal and cardiac muscle. 76 To manage reductions in coronary blood flow while diving, the seal heart relies largely on its large glycogen stores for fuel, resulting in lactate and H ϩ ion accumulation. 79, 82 On resurfacing, the myocardium resumes using lactate as fuel and shows no evidence of ischemic dilation of the left ventricle or ST segment elevation. 83 Elevated antioxidant levels in the blood and tissue of diving mammals may, in part, counter oxidative stress resulting from the rapid apnea to reoxygenation transition during diving. 84, 85 Understanding the mechanisms of how diving seals mobilize their high glycogen stores for fuel 82 could aid in identifying therapeutic target treatments of glycogen storage diseases in humans in which defects in muscle glycogen synthesis or breakdown result in protein degradation, atrophy, hypertrophic cardiomyopathy, cardiomyocyte degeneration, and fibrosis. 86 Sleep apnea research also might benefit from the study of seals that are apneic for most of their sleep time, with arterial PO 2 decreasing precipitously from a maximum of 108 torr to a minimum of 18 torr. 81, 87 Despite the increased prevalence and heightened awareness, obstructive sleep ap-nea is still underdiagnosed and appears to be associated with diabetes, coronary heart disease, heart failure, and cardiac arrhythmias. 88 -90 The number of patients with obese hypoventilation syndrome, characterized by obesity, hypoventilation, and sleepiness, is increasing. 91 Obese hypoventilation syndrome treatment options and long-term outcomes have been poorly studied, 91 and diving mammals may provide ideal animal models to better-understand obstructive sleep apnea and obese hypoventilation syndrome. 92 In addition to improving our understanding of sleep apnea, the study of seals might contribute to increased understanding of insulin resistance in people. Postweaned elephant seal pups experience prolonged fasts of 8 to 12 weeks when unattended by their mothers 93 and, as a result, the pups become insulinresistant. 94, 95 Yet, elephant seals have evolved mechanisms that permit fasting pups to continue to appropriately normalize carbohydrate and blood glucose levels. 96, 97 Elucidation of these processes for glucose regulation in diving mammals could result in improved treatments for diabetes in people. 98
Conclusions
Evolution has produced a diverse array of animal species with unique phenotypes that provide extraordinary models for understanding human disease processes and clues for the development of new effective means for the early identification, treatment, and prevention of disease. In this way, these unique animal species fulfill Krogh's principle. The National Heart, Lung, and Blood Institute supported studies of animal species adapted to survive severe environmental conditions, which mimic or would result in human heart, lung, blood, and sleep disorders, that are demonstrating that the mechanisms used by these species for metabolic regulation, organ function maintenance, antioxidant defenses, and O 2 transport have great potential for the development of new treatments for human disorders. These examples, along with the past successes of applying Krogh's Principle to the study of animal species with extraordinary phenotypes, underscore the power of using nature's solutions to guide the development of novel therapies to treat and prevent human disease.
Sources of Funding
H.V.C. was supported by the NSF while working at the Foundation. Any views expressed are those of the authors and do not necessarily reflect those of the National Science Foundation. R.P.W. and D.A.L. are employees of National Heart, Lung, and Blood Institute at National Institutes of Health, and although their participation in the development of this manuscript was performed as an official duty activity, the views expressed do not necessarily represent those of the Institutes.
Disclosures
None.
